These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29332307)

  • 1. Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography.
    Kraak RP; Kajita AH; Garcia-Garcia HM; Henriques JPS; Piek JJ; Arkenbout EK; van der Schaaf RJ; Tijssen JGP; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):E106-E114. PubMed ID: 29332307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
    Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
    JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
    Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.
    Karanasos A; Van Mieghem N; van Ditzhuijzen N; Felix C; Daemen J; Autar A; Onuma Y; Kurata M; Diletti R; Valgimigli M; Kauer F; van Beusekom H; de Jaegere P; Zijlstra F; van Geuns RJ; Regar E
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography.
    Hoppmann P; Rai H; Colleran R; Kufner S; Wiebe J; Cassese S; Joner M; Laugwitz KL; Kastrati A; Byrne RA
    Cardiovasc Revasc Med; 2020 Mar; 21(3):361-366. PubMed ID: 31231028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation.
    Brown AJ; McCormick LM; Braganza DM; Bennett MR; Hoole SP; West NE
    Catheter Cardiovasc Interv; 2014 Jul; 84(1):37-45. PubMed ID: 24403223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial.
    Lee SY; Kang DY; Hong SJ; Ahn JM; Ahn CM; Park DW; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Hong MK
    Circ Cardiovasc Interv; 2020 Jan; 13(1):e008383. PubMed ID: 32525410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry.
    Yamaji K; Ueki Y; Souteyrand G; Daemen J; Wiebe J; Nef H; Adriaenssens T; Loh JP; Lattuca B; Wykrzykowska JJ; Gomez-Lara J; Timmers L; Motreff P; Hoppmann P; Abdel-Wahab M; Byrne RA; Meincke F; Boeder N; Honton B; O'Sullivan CJ; Ielasi A; Delarche N; Christ G; Lee JKT; Lee M; Amabile N; Karagiannis A; Windecker S; Räber L
    J Am Coll Cardiol; 2017 Nov; 70(19):2330-2344. PubMed ID: 29096803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial.
    Sotomi Y; Onuma Y; Dijkstra J; Miyazaki Y; Kozuma K; Tanabe K; Popma JJ; de Winter RJ; Serruys PW; Kimura T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):59-66. PubMed ID: 28158421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term invasive follow-up of bioresorbable vascular scaffold: Optical Coherence Tomography assessment of jailed side branches.
    Paradies V; Smits PC; Vachojannis GJ; Royaards KJ; Wassing J; van der Ent M
    Cardiovasc Revasc Med; 2018 Apr; 19(3 Pt A):279-285. PubMed ID: 29066339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
    Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM
    EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry.
    Pereira GTR; La Manna A; Ichibori Y; Vergara-Martel A; Ramos Nascimento B; Samdani AJ; Capodanno D; D'Agosta G; Gravina G; Venuti G; Tamburino C; F Attizzani G
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1767-1776. PubMed ID: 31175527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold.
    Kochman J; Kołtowski Ł; Tomaniak M; Jąkała J; Proniewska K; Legutko J; Roleder T; Piertrasik A; Rdzanek A; Kochman W; Brugaletta S; Opolski G; Regar E
    EuroIntervention; 2018 Apr; 13(18):e2201-e2209. PubMed ID: 29155384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes.
    Abdelaziz HK; Abuomara HZ; Ali MH; Eichhofer J; Patel B; Saad M
    Coron Artery Dis; 2019 Jun; 30(4):263-269. PubMed ID: 30883433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.
    Toušek P; Kočka V; Malý M; Lisa L; Buděšínský T; Widimský P
    Heart Vessels; 2016 Jun; 31(6):841-5. PubMed ID: 25896128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.